Cover Image

Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin

To investigate the effect of medrogestone on bone mineral density (BMD) and bone turnover under conditions of estrogen withdrawal, premenopausal women with endometriosis were treated with goserelin (Zoladex®), combined with either placebo (group A, n = 12) or 10 mg medrogestone (Prothil®, group B, n...

Full description

Saved in:
Bibliographic Details
Main Authors: Sillem, Martin (Author) , Parviz, Maryam (Author) , Woitge, Henning W. (Author) , Kiesel, L. (Author) , Ulrich, U. (Author) , Holst, Thomas von (Author) , Runnebaum, Benno (Author) , Ziegler, Reinhard (Author) , Seibel, Markus J. (Author)
Format: Article (Journal)
Language:English
Published: 1999
In: Experimental and clinical endocrinology & diabetes
Year: 1999, Volume: 107, Issue: 6, Pages: 379-385
ISSN:1439-3646
DOI:10.1055/s-0029-1212129
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1055/s-0029-1212129
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0029-1212129
Get full text
Author Notes:M. Sillem, M. Parviz, H.W. Woitge, L. Kiesel, U. Ulrich, Th. von Holst, B. Runnebaum, R. Ziegler, M.J. Seibel
Description
Summary:To investigate the effect of medrogestone on bone mineral density (BMD) and bone turnover under conditions of estrogen withdrawal, premenopausal women with endometriosis were treated with goserelin (Zoladex®), combined with either placebo (group A, n = 12) or 10 mg medrogestone (Prothil®, group B, n = 11) for six months, and followed for an additional six months. Lumbar spine BMD was measured at 0 and 6 month. Markers of bone turnover were serum bone alkaline phosphatase (sBAP) and osteocalcin (sOC) by ELISA, and urinary total pyridinoline (uPYD) and deoxypyridinoline crosslinks (uDPD) by HPLC.
Item Description:Elektronische Reproduktion der Print-Ausgabe, 14. Juli 2009
Physical Description:Online Resource
ISSN:1439-3646
DOI:10.1055/s-0029-1212129

Similar Items